SEC Form 4 · accession 0001181431-15-008177
Adverum Biotechnologies, Inc. · ADVM
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Thomas W. Chalberg
Officer — Chief Executive Officer · Director
Period of report
Jun 10, 2015
Accepted (ET)
Jun 11, 2015 · 6:21 pm EDT
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001501756
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common StockF2 | Jun 10, 2015 | S | 5,035 | $36.8883 | D | 278,953 | D | |
| Common StockF3 | Jun 10, 2015 | S | 12,970 | $38.0369 | D | 265,983 | D | |
| Common StockF4 | Jun 10, 2015 | S | 6,995 | $38.9025 | D | 258,988 | D | |
| Common StockF5 | holding | — | — | — | 420,000 | I | See Footnote | |
| Common StockF6 | holding | — | — | — | 420,000 | I | See Footnote | |
| Common StockF7 | holding | — | — | — | 413 | I | See Footnote |
Table II — derivative securities
No Table II lines on this filing.
Explanation of responses
- F1Transaction made pursuant to a 10b5-1 trading plan adopted by the Reporting Person.
- F2This transaction was executed in multiple trades in prices ranging from $36.4300 to $37.4000, inclusive. The price reported in Column 4 above reflects the weighted average sales price. The Reporting Person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote.
- F3This transaction was executed in multiple trades in prices ranging from $37.4600 to $38.4550, inclusive. The price reported in Column 4 above reflects the weighted average sales price. The Reporting Person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote.
- F4This transaction was executed in multiple trades in prices ranging from $38.5900 to $39.1050, inclusive. The price reported in Column 4 above reflects the weighted average sales price. The Reporting Person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote.
- F5The Shares are held directly by Thomas W. Chalberg, as Trustee of the Thomas W. Chalberg 2014 Grantor Retained Annuity Trust under agreement dated April 30, 2014.
- F6The Shares are held directly by the Stefanie R. Chalberg 2014 Grantor Retained Annuity Trust under agreement dated April 30, 2014.
- F7The Shares are held directly by the 2009 Chalberg Family Trust, Thomas W. Chalberg, Jr. and Stefanie Raue Chalberg, Trustees.